Heron Therapeutics Falls 11%, Company Says FDA Has Not Concluded A Scheduled Review

Heron Therapeutics Inc HRTX announced on Monday that the U.S. Food and Drug Administration (FDA) has not taken any action on its New Drug Application (NDA) for SUSTOL.

The FDA informed Heron Therapeutics that it has not yet concluded a review of the NDA despite a January 17, 2016, deadline expected late February.

Related Link: Heron Therapeutics Announces No Update

Shares of Heron Therapeutics were trading lower by more than 4 percent shortly after Monday's market open, and have since continued to drop.

Heron Therapeutics added that the FDA could not yet provide an anticipated action date but will communicate a new action date later on this week.

At the time of this publication, heron was trading down 11.53 percent on the day at $16.57.